Todd Franklin Watanabe serves as the President and Chief Executive Officer at Arcutis Biotherapeutics Inc., a position he has held since the company's inception. With a robust background in the biopharmaceutical industry, Watanabe has been instrumental in steering Arcutis towards its mission of developing innovative treatments for immune-mediated dermatological diseases. Prior to joining Arcutis, he held significant leadership roles at companies such as Amgen and Astellas Pharma, where he honed his skills in strategic planning and corporate development. Watanabe's career is marked by a series of notable achievements that underscore his expertise and leadership in the biotech sector. At Amgen, he played a key role in the development and commercialization of several blockbuster drugs, contributing to the company's growth and success. His tenure at Astellas Pharma saw him leading the company's oncology business unit, where he successfully expanded the portfolio and strengthened the company's market position. These experiences have equipped him with a deep understanding of the complexities involved in bringing new therapies to market. As President and CEO of Arcutis Biotherapeutics Inc., Watanabe is responsible for overseeing the company's overall strategy and operations. Under his leadership, Arcutis has made significant strides in advancing its clinical pipeline, with a focus on developing novel therapies for conditions such as psoriasis and atopic dermatitis. Watanabe's vision for the company is to become a leader in dermatology, and he continues to drive innovation and growth through strategic partnerships and a commitment to scientific excellence.